Do comorbidities impact persistence of first tumor necrosis factor inhibitor treatment in rheumatoid arthritis? Data from Turkbio

İnel, T. YüceKocaer, S. B.Erez, Y.Gülle, S.Karakaş, A.Avşar, A. KökenUslu, S.Can, G.Sarı, I.Birlik, M.Dalkılıç, E.Pehlivan, Y.Akar, S.Göker, B.Çetin, G. YıldırımHaznedaroğlu, S.Yavuz, S.Pırıldar, T.Direskeneli, H.Akkoç, N.Önen, F.Turkbio Registry Group2024-07-042024-07-042020-06-010003-4967https://doi.org/10.1136/annrheumdis-2020-eular.1599https://ard.bmj.com/content/79/Suppl_1/982.1https://hdl.handle.net/11452/42883enScience & technologyLife sciences & biomedicineRheumatologyDo comorbidities impact persistence of first tumor necrosis factor inhibitor treatment in rheumatoid arthritis? Data from TurkbioMeeting Abstract00055590500317197897879Supplement 110.1136/annrheumdis-2020-eular.1599